Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: High Salt Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.

NCT06719219
View directory record Official record
Conditions
Staphylococcus (S.) Aureus Infection
Interventions
LTB-SA7, Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Phase 1 Interventional

Topical Naloxone to Diagnose Ocular Pain

NCT04454281
View directory record Official record
Conditions
Dry Eye Syndromes, Neuropathic Pain
Interventions
Naloxone Hydrochloride 0.4 MG/ML
Drug
Lead sponsor
Seema Capoor
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FFA-Induced Hypertension and Endothelial Dysfunction

NCT00589888
View directory record Official record
Conditions
Endothelial Dysfunction, Hypertension
Interventions
Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 24, 2026, 4:48 AM EDT
Not listed Phase 2 Interventional

Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

NCT02908035
View directory record Official record
Conditions
Chronic Limb Ischemia
Interventions
Temsirolimus, Saline
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 24, 2026, 4:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

NCT06611371
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
IVT GBS-06, Placebo
Biological
Lead sponsor
Inventprise Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 24, 2026, 4:48 AM EDT
Recruiting Phase 2 Interventional

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT03418038
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions
Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography, Decitabine and Cedazuridine
Dietary Supplement · Drug · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
4
States / cities
Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
145
States / cities
Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Phase 1 Interventional

Safety Study of TPI-287 to Treat CBS and PSP

NCT02133846
View directory record Official record
Conditions
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions
TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 24, 2026, 4:48 AM EDT
Not listed Phase 1Phase 2 Interventional

Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients

NCT01626469
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Captopril, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

NCT00117650
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease, Atherosclerosis
Interventions
Ad2/HIF-1α/VP16, Saline (Placebo Control)
Biological · Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
40 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
35
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Phase 1 Interventional

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

NCT04606602
View directory record Official record
Conditions
Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
Interventions
SLN360, Placebo
Drug
Lead sponsor
Silence Therapeutics plc
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Jacksonville, Florida • Port Orange, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients

NCT01635101
View directory record Official record
Conditions
Acute Pain
Interventions
IV Acetaminophen, IV Control
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
1 Day to 2 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
22
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 24, 2026, 4:48 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dietary Sodium, Oxidative Stress, and Pulsatile Hemodynamics

NCT04233957
View directory record Official record
Conditions
Sodium Excess
Interventions
High Sodium, Placebo
Dietary Supplement · Other
Lead sponsor
University of Delaware
Other
Eligibility
21 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 24, 2026, 4:48 AM EDT
Active, not recruiting Not applicable Interventional

Functional Snack Foods With Safflower Oil and Soy in Postmenopausal Women Having Metabolic Syndrome

NCT02199054
View directory record Official record
Conditions
Metabolic Syndrome, Overweight
Interventions
wheat-safflower oil pretzels, soy-safflower oil pretzels, control wheat pretzels
Other
Lead sponsor
Ohio State University
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 24, 2026, 4:48 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Floatation Experience in Nurses and Physicians

NCT05977894
View directory record Official record
Conditions
Burnout, Professional, Negative Affect, Positive Affect, Wellbeing, Burnout, Psychological
Interventions
Reduced Environmental Stimulation Therapy
Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 4:48 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NCT03126916
View directory record Official record
Conditions
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 30 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Macronutrient Effects on Alzheimer's Disease (MEAL-2)

NCT02463084
View directory record Official record
Conditions
Prediabetic State, Insulin Resistance, Middle Age, Prehypertension, Mild Cognitive Impairment
Interventions
Low Diet, High Diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
45 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 24, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

NCT02732015
View directory record Official record
Conditions
Locally Advanced Sarcoma
Interventions
Dexamethasone, Doxorubicin, Fosaprepitant Dimeglumine, Ifosfamide, Laboratory Biomarker Analysis, Mesna, Ondansetron, Questionnaire Administration, Rolapitant Hydrochloride, Vincristine Sulfate
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Phase 2 Interventional

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793
View directory record Official record
Conditions
Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions
IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

NCT03347708
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
IDCT, Saline Solution, Sodium Hyaluronate
Biological · Drug
Lead sponsor
DiscGenics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Not applicable Interventional

When the Kidney Reacts to Nutritional Changes

NCT04142138
View directory record Official record
Conditions
Prehypertension
Interventions
DASH
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 24, 2026, 4:48 AM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 4:48 AM EDT
Suspended Phase 2Phase 3 Interventional

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

NCT01810913
View directory record Official record
Conditions
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
Drug · Procedure · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
338
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 4:48 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

NCT01607450
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Healthy
Interventions
GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 24, 2026, 4:48 AM EDT